School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada.
Boston University School of Medicine, Boston, MA, USA.
Osteoarthritis Cartilage. 2022 Sep;30(9):1263-1269. doi: 10.1016/j.joca.2022.06.002. Epub 2022 Jun 11.
To assess the relation of obesity to opioid use in people with or at risk of knee osteoarthritis (OA), and the extent to which this association is mediated by number of painful joints or depressive symptoms.
We used data from the Multicenter Osteoarthritis Study, a longitudinal cohort of older adults with or at risk of knee OA. Opioid use was identified by prescription medications and self-report. Obesity was defined as BMI ≥ 30 kg/m. Multi-joint pain was assessed using a standardized body homunculus, and depressive symptoms using the Center for Epidemiological Studies Depression scale. We quantified the direct and indirect effect of obesity on opioid use through the number of painful joints or depressive symptoms using causal mediation analysis by natural-effects models.
We studied 2,335 participants (mean age: 68; mean BMI 31 kg/m; 60% women). Persons with obesity had ∼50% higher odds of opioid use than those without. Estimates of indirect (mediated) effect by the number of painful joints and depressive symptoms suggested an increased odds of opioid use by 34% (odds ratio [OR] = 1.34, 95% CI: 1.04, 1.70) and 35% (OR 1.35, 95% CI: 1.05, 1.71), respectively, in obese vs non-obese individuals. The total effect of obesity on opioid use was higher in women than in men.
Multi-joint pain and depressive symptoms partially explained greater opioid use among obese persons with knee OA, demonstrating that the negative impact of obesity on knee OA extends beyond its influence on knee pain and structural progression.
评估肥胖与膝骨关节炎(OA)患者或有患病风险者的阿片类药物使用之间的关系,以及这种关联在多大程度上受到关节疼痛数量或抑郁症状的影响。
我们使用了多中心骨关节炎研究的数据,这是一个针对有或有患膝骨关节炎风险的老年人的纵向队列研究。阿片类药物的使用通过处方药物和自我报告来确定。肥胖定义为 BMI≥30kg/m²。多关节疼痛使用标准化身体同象图进行评估,抑郁症状使用流行病学研究中心抑郁量表进行评估。我们通过自然效应模型的因果中介分析,通过疼痛关节或抑郁症状的数量来量化肥胖对阿片类药物使用的直接和间接影响。
我们研究了 2335 名参与者(平均年龄:68 岁;平均 BMI 31kg/m²;60%为女性)。与非肥胖者相比,肥胖者使用阿片类药物的可能性高出约 50%。通过疼痛关节和抑郁症状的数量来估计间接(中介)效应表明,肥胖者使用阿片类药物的可能性增加了 34%(比值比 [OR] = 1.34,95%置信区间:1.04,1.70)和 35%(OR 1.35,95% CI:1.05,1.71)。肥胖对阿片类药物使用的总效应在女性中高于男性。
多关节疼痛和抑郁症状部分解释了肥胖的膝骨关节炎患者中阿片类药物使用的增加,这表明肥胖对膝骨关节炎的负面影响超出了其对膝关节疼痛和结构进展的影响。